Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy | Zendy

Patrícia Duarte Deps | Zendy; Patrícia Guerra | Zendy; Sofia Nasser | Zendy; Marisa Simon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy

Author(s) -

Patrícia Duarte Deps,

Patrícia Guerra,

Sofia Nasser,

Marisa Simon

Publication year - 2012

Publication title -

leprosy review

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.437

H-Index - 43

eISSN - 2162-8807

pISSN - 0305-7518

DOI - 10.47276/lr.83.3.305

Subject(s) - dapsone , medicine , leprosy , clofazimine , anemia , rifampicin , hematocrit , adverse effect , surgery , hemoglobin , hemolysis , dermatology , gastroenterology , tuberculosis , pathology

Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin. Dapsone is known to cause hemolytic anemia (HA) and this adverse event during MDT seems to be more frequent than reported. The aim of this report is to discuss and grade HA due to dapsone during MDT treatment for leprosy.METHODSThis is a retrospective study of 194 leprosy patients from a Leprosy Control Programme Unit in Vit6ria-ES, Brazil.RESULTSHA was observed in 48 (24.7%) patients and occurred within the first 3 months in 51% of these. Mean hematocrit levels fell from 38.5 to 31.5 and hemoglobin from 12.8 to 10.3.CONCLUSIONDapsone used in the MDT regime for leprosy decreases the hematocrit and hemoglobin levels due to a low grade hemolysis, which can result in significant anemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research